Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.1
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell